SAREPTA THERAPEUTICS, INC. Current Federal Tax Expense (Benefit)
SAREPTA THERAPEUTICS, INC. (SRPT) reported Current Federal Tax Expense (Benefit) of -$1.27 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentFederalTaxExpenseBenefit · last filed 2026-03-02
- SAREPTA THERAPEUTICS, INC. current federal tax expense (benefit) for the quarter ending 2023-12-31 was $80.00K.
- SAREPTA THERAPEUTICS, INC. current federal tax expense (benefit) for the quarter ending 2023-09-30 was $4.10M.
- SAREPTA THERAPEUTICS, INC. current federal tax expense (benefit) for the quarter ending 2023-06-30 was $2.90M.
- SAREPTA THERAPEUTICS, INC. current federal tax expense (benefit) for the quarter ending 2023-03-31 was $900.00K.
- SAREPTA THERAPEUTICS, INC. current federal tax expense (benefit) for fiscal 2025 was -$1.27M, a 125.06% decline from fiscal 2024.
- SAREPTA THERAPEUTICS, INC. current federal tax expense (benefit) for fiscal 2024 was $5.06M, a 21.15% increase from fiscal 2023.
- SAREPTA THERAPEUTICS, INC. current federal tax expense (benefit) for fiscal 2023 was $4.18M.
- SAREPTA THERAPEUTICS, INC. current federal tax expense (benefit) for fiscal 2022 was $0.00.
| Period end | Current Federal Tax Expense (Benefit) 3 month | Current Federal Tax Expense (Benefit) 6 month | Current Federal Tax Expense (Benefit) 9 month | Current Federal Tax Expense (Benefit) 12 month | Current Federal Tax Expense (Benefit) 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | -$1.27M 10-K · filed 2026-03-02 | ||||
| 2024-12-31 | $5.06M 10-K · filed 2026-03-02 | ||||
| 2023-12-31 | $80.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $4.18M derived: sum of 2 quarters · filed 2026-03-02 | $7.08M derived: sum of 3 quarters · filed 2026-03-02 | $4.18M 10-K · filed 2026-03-02 | |
| 2023-09-30 | $4.10M 10-Q · filed 2024-11-06 | $7.00M derived: sum of 2 quarters · filed 2024-11-06 | $4.10M 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | $2.90M 10-Q · filed 2024-08-07 | $2.90M 10-Q · filed 2024-08-07 | |||
| 2023-03-31 | $900.00K 10-Q · filed 2024-05-01 | ||||
| 2022-12-31 | $0.00 10-K · filed 2025-02-28 | ||||
| 2021-12-31 | $0.00 10-K · filed 2024-02-28 | ||||
| 2020-12-31 | $4.00K 10-K · filed 2023-02-28 | ||||
| 2018-12-31 | -$110.00K 10-K · filed 2021-03-01 | ||||
| 2017-12-31 | $204.00K 10-K · filed 2020-02-26 | $200.00K 10-K · filed 2018-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |